TAIMED BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88 TWD | +0.92% |
|
+1.73% | +7.32% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 24,991 | 21,212 | 17,813 | 17,843 | 20,746 | 24,025 | - |
| Enterprise Value (EV) 1 | 23,717 | 21,176 | 17,798 | 18,305 | 21,217 | 23,201 | 22,238 |
| P/E ratio | -43.1 x | -115 x | -37.8 x | -66.1 x | -106 x | 35.9 x | 23.2 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 35.5 x | 29.4 x | 43.1 x | 31.7 x | 42.2 x | 10.7 x | 12.3 x |
| EV / Revenue | 33.7 x | 29.3 x | 43 x | 32.5 x | 43.1 x | 10.3 x | 11.4 x |
| EV / EBITDA | -79.7 x | 3,016 x | -54 x | -517 x | -1,957 x | 23.1 x | 14.6 x |
| EV / FCF | -30.5 x | -83.3 x | -81.1 x | - | -673 x | -58.4 x | 30.8 x |
| FCF Yield | -3.28% | -1.2% | -1.23% | - | -0.15% | -1.71% | 3.25% |
| Price to Book | 6.96 x | 5.54 x | 6.06 x | 6.58 x | 8.09 x | 9.27 x | 6.35 x |
| Nbr of stocks (in thousands) | 252,183 | 252,220 | 252,311 | 252,374 | 252,999 | 273,010 | - |
| Reference price 2 | 99.10 | 84.10 | 70.60 | 70.70 | 82.00 | 88.00 | 88.00 |
| Announcement Date | 3/26/20 | 3/26/21 | 3/31/22 | 3/10/23 | 3/20/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 704.5 | 722.5 | 413.4 | 563 | 491.8 | 2,245 | 1,949 |
| EBITDA 1 | -297.5 | 7.022 | -329.7 | -35.41 | -10.84 | 1,003 | 1,527 |
| EBIT 1 | -390 | -132.8 | -486.4 | -191.9 | -166.2 | 760 | 1,180 |
| Operating Margin | -55.36% | -18.38% | -117.64% | -34.08% | -33.8% | 33.85% | 60.54% |
| Earnings before Tax (EBT) 1 | -578.7 | -183.3 | -470.9 | -269.3 | -194.8 | 787.9 | 1,200 |
| Net income 1 | -578.7 | -183.3 | -470.9 | -269.3 | -194.8 | 630.3 | 960 |
| Net margin | -82.14% | -25.37% | -113.91% | -47.83% | -39.61% | 28.08% | 49.26% |
| EPS 2 | -2.300 | -0.7300 | -1.870 | -1.070 | -0.7700 | 2.454 | 3.800 |
| Free Cash Flow 1 | -776.9 | -254.3 | -219.4 | - | -31.54 | -397 | 723 |
| FCF margin | -110.27% | -35.2% | -53.08% | - | -6.41% | -17.68% | 37.1% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 47.35% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 75.31% |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/26/21 | 3/31/22 | 3/10/23 | 3/20/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 75.86 | 40.67 | 99.28 | 96.58 | 326.5 | 71.77 | 104.2 | 157.6 | 158.2 | 178.9 | 151 | 228 | 229 |
| EBITDA 1 | -203.2 | -63.11 | -16.43 | - | - | -32.02 | -26.47 | 35.41 | 12.23 | 1.706 | 76 | 113 | 111 |
| EBIT 1 | -242.2 | -102.2 | -55.56 | -59.41 | 25.33 | -71.14 | -65.3 | -3.289 | -26.5 | -37.05 | -21 | 16 | 14 |
| Operating Margin | -319.34% | -251.31% | -55.96% | -61.52% | 7.76% | -99.13% | -62.64% | -2.09% | -16.75% | -20.7% | -13.91% | 7.02% | 6.11% |
| Earnings before Tax (EBT) 1 | -298.7 | -119.8 | -75.77 | - | - | -80.8 | -47.84 | -5.878 | -60.29 | -16.04 | -19 | 19 | 18 |
| Net income 1 | -298.7 | -119.8 | -75.77 | -35.98 | -37.78 | -80.8 | -47.84 | -5.878 | -60.29 | -16.04 | -15 | 19 | 14 |
| Net margin | -393.77% | -294.47% | -76.31% | -37.25% | -11.57% | -112.59% | -45.89% | -3.73% | -38.1% | -8.96% | -9.93% | 8.33% | 6.11% |
| EPS 2 | -1.190 | -0.4700 | -0.3000 | -0.1400 | -0.1500 | -0.3200 | -0.1900 | -0.0200 | -0.2400 | -0.0600 | -0.0600 | 0.0800 | 0.0600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/13/22 | 8/15/22 | 11/11/22 | 3/10/23 | 5/12/23 | 8/11/23 | 11/14/23 | 3/20/24 | 5/14/24 | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 462 | 471 | - | - |
| Net Cash position 1 | 1,274 | 36.1 | 15.6 | - | - | 824 | 1,787 |
| Leverage (Debt/EBITDA) | - | - | - | -13.04 x | -43.43 x | - | - |
| Free Cash Flow 1 | -777 | -254 | -219 | - | -31.5 | -397 | 723 |
| ROE (net income / shareholders' equity) | -15.1% | -5.24% | -14.8% | -9.52% | -7.38% | 21.6% | 31.8% |
| ROA (Net income/ Total Assets) | -12.2% | -3.69% | -9.6% | - | -4.87% | -3.61% | 21.8% |
| Assets 1 | 4,761 | 4,964 | 4,904 | - | 3,997 | -17,461 | 4,404 |
| Book Value Per Share 2 | 14.20 | 15.20 | 11.70 | 10.70 | 10.10 | 9.500 | 13.90 |
| Cash Flow per Share 2 | -2.600 | -0.8000 | -0.8400 | -2.400 | -0.1000 | -0.1400 | 4.210 |
| Capex 1 | 122 | 53.6 | 8.17 | - | 5.94 | 55 | 100 |
| Capex / Sales | 17.25% | 7.42% | 1.98% | - | 1.21% | 2.45% | 5.13% |
| Announcement Date | 3/26/20 | 3/26/21 | 3/31/22 | 3/10/23 | 3/20/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
88
TWD
Average target price
133.7
TWD
Spread / Average Target
+51.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.32% | 738M | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- 4147 Stock
- Financials TaiMed Biologics Inc.
